Over the past 5 years, several new immunotherapy treatments have been tested for
metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different …

The tumor microenvironment consists of tumor cells, extracellular matrix, blood vessels, and
non-tumor cells such as fibroblasts and immune cells. Crosstalk among components of this …

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma
and has the highest mortality rate. For metastatic RCC, systemic drug therapy is the most …

Global survival studies have shown favorable development in renal cell carcinoma (RCC)
treatment but few studies have considered extended periods or covered populations for …

Survival studies are an important indicator of the success of cancer control. We analyzed the
5‐year relative survival in 23 solid cancers in Denmark, Finland, Norway and Sweden over a …

Simple Summary Cancers in the urinary bladder and kidney are common in men and rarer
in women. Cigarette smoking is a shared risk factor for both of these cancers. Some 50 years …

The advent of micro-physiological systems (MPS) in biomedical research has enabled the
introduction of more complex and relevant physiological into in vitro models. The recreation …

Kidney cancer and chronic kidney disease are two renal pathologies with very different
clinical management strategies and therapeutical options. Nonetheless, the cellular and …

Cancer morbimortality is still a great concern despite advances in research and therapies.
Histamine and its receptors' ligands can modulate different biological responses according …

Over the last decade, there have been substantial progress in the field of systemic therapy
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …